BTIG Maintains Buy on Guardant Health, Raises Price Target to $195
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $190 to $195.
BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $190 to $195.